Statement: Patients in the primary trial and the secondary trial did not have any of the same adverse events, except Supraventricular extrasystoles which was the most common event in both trials.
Primary_evidence: Adverse Events 1:   Total: 6/25 (24.00%)   Supraventricular extrasystoles 1/25 (4.00%)   Ventricular extrasystoles 1/25 (4.00%)   Ascites 2/25 (8.00%)   Diarrhea 1/25 (4.00%)   Nausea 1/25 (4.00%)   Pancreatitis 1/25 (4.00%)   Small intestinal obstruction 1/25 (4.00%)   Vomiting 1/25 (4.00%)   Bile duct obstruction 1/25 (4.00%)   Portal hypertension 1/25 (4.00%)
Secondary_evidence: Adverse Events 1:   Total: 6/19 (31.58%)   Febrile neutropenia  [1]1/19 (5.26%)   Fatigue  [1]1/19 (5.26%)   Pyrexia  [1]1/19 (5.26%)   Fracture  [1]1/19 (5.26%)   Hip Fracture  [1]1/19 (5.26%)   Headache  [2]1/19 (5.26%)